The KDIGO practice guideline on glomerulonephritis: Reading between the (guide)lines-application to the individual patient

Kidney International

Volumn 82, Issue 8, 2012, Pages 840-856

  Radhakrishnan, Jai ^a   Cattran, Daniel C ^b  

^a NewYork Presbyterian Hospital   (United States)

^b UNIVERSITY HEALTH NETWORK   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

ALKYLATING AGENT; ANGIOTENSIN RECEPTOR ANTAGONIST; AZATHIOPRINE; CALCINEURIN INHIBITOR; CORTICOSTEROID; CYCLOPHOSPHAMIDE; CYCLOSPORIN; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; IMMUNOSUPPRESSIVE AGENT; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; PREDNISOLONE; PREDNISONE; TACROLIMUS;

ANCA ASSOCIATED VASCULITIS; CLINICAL DECISION MAKING; DIALYSIS; DRUG CHOICE; DRUG DOSE INCREASE; DRUG DOSE REDUCTION; DRUG DOSE TITRATION; DRUG INDICATION; DRUG INTERMITTENT THERAPY; DRUG MEGADOSE; FOCAL GLOMERULONEPHRITIS; FOCAL GLOMERULOSCLEROSIS; GENETIC ANALYSIS; GLOMERULONEPHRITIS; GLOMERULOSCLEROSIS; HUMAN; IMMUNOGLOBULIN A NEPHROPATHY; IMMUNOSUPPRESSIVE TREATMENT; KIDNEY BIOPSY; LUPUS ERYTHEMATOSUS NEPHRITIS; MAINTENANCE THERAPY; MEDICAL INFORMATION; MEMBRANOUS GLOMERULONEPHRITIS; NONHUMAN; PLASMAPHERESIS; PRACTICE GUIDELINE; PRIORITY JOURNAL; PROTEINURIA; RELAPSE; REVIEW; SEGMENTAL NECROTIZING GLOMERULOSCLEROSIS; SINGLE DRUG DOSE; TREATMENT PLANNING;

EID: 84867051576     PISSN: 00852538     EISSN: 15231755     Source Type: Journal    
DOI: 10.1038/ki.2012.280     Document Type: Review

References (43)

1. Field MJ, Cohr KN (eds). Clinical Practice Guidelines: Directions for a New Program. Institute of Medicine: Washington, 1990.
2. Woolf SH, Grol R, Hutchinson A et al. Clinical guidelines-potential benefits, limitations, and harms of clinical guidelines. Brit Med J 1999; 318: 527-530.
3. Berger JT, Rosner F. The ethics of practice guidelines. Arch Intern Med 1996; 156: 2051-2056.
4. Grimshaw JM, Russell IT. Effect of clinical guidelines on medical-practice-a systematic review of rigorous evaluations. Lancet 1993; 342: 1317-1322.
5. Grimshaw JM, Russell IT. Achieving health gain through clinical guidelines II: ensuring guidelines change medical practice. Qual Health Care 1994; 3: 45-52.
6. Deegens JKJ, Dijkman HBPM, Borm GF et al. Podocyte foot process effacement as a diagnostic tool in focal segmental glomerulosclerosis. Kidney Int 2008; 74: 1568-1576.
7. Praga M, Morales E, Herrero JC et al. Absence of hypoalbuminemia despite massive proteinuria in focal segmental glomerulosclerosis secondary to hyperfiltration. Am J Kid Dis 1999; 33: 52-58.
8. Kambham N, Markowitz GS, Valeri AM et al. Obesity-related glomerulopathy: an emerging epidemic. Kidney Int 2001; 59: 1498-1509.
9. Praga M, Borstein B, Andres A et al. Nephrotic proteinuria without hypoalbuminemia-clinical characteristics and response to angiotensinconverting enzyme-inhibition. Am J Kid Dis 1991; 17: 330-338.
10. Heisel O, Heisel R, Balshaw R et al. New onset diabetes mellitus in patients receiving calcineurin inhibitors: A systematic review and meta-analysis. Am J Transplant 2004; 4: 583-595.
11. Malina M, Cinek O, Janda J et al. Partial remission with cyclosporine A in a patient with nephrotic syndrome due to NPHS2 mutation. Pediatr Nephrol 2009; 24: 2051-2053.
12. Callis L, Vila A, Carrera M et al. Long-term effects of cyclosporine A in Alport's syndrome. Kidney Int 1999; 55: 1051-1056.
13. Ambalavanan S, Fauvel JP, Sibley RK et al. Mechanism of the antiproteinuric effect of cyclosporine in membranous nephropathy. J Am Soc Nephrol 1996; 7: 290-298.
14. Faul C, Donnelly M, Merscher-Gomez S et al. The actin cytoskeleton of kidney podocytes is a direct target of the antiproteinuric effect of cyclosporine A. Nat Med 2008; 14: 931-938.
15. Markowitz GS, D'Agati VD. The ISN/RPS 2003 classification of lupus nephritis: An assessment at 3 years. Kidney Int 2007; 71: 491-495.
16. Nasr SH, D'Agati VD, Park HR et al. Necrotizing and crescentic lupus nephritis with antineutrophil cytoplasmic antibody seropositivity. Clin J Am Soc Nephrol 2008; 3: 682-690.
17. Hsieh C, Chang A, Brandt D et al. Predicting outcomes of lupus nephritis with tubulointerstitial inflammation and scarring. Arthritis Care Res 2011; 63: 865-874.
18. Koo H, Kim Y, Lee S et al. The effects of cyclophosphamide and mycophenolate on end-stage renal disease and death of lupus nephritis. Lupus 2011; 20: 1442-1449.
19. Pisoni CN, Sanchez FJ, Karim Y et al. Mycophenolate mofetil in systemic lupus erythematosus: efficacy and tolerability in 86 patients. J Rheumatol 2005; 32: 1047-1052.
20. Cortes-Hernandez J, Torres-Salido MT, Medrano AS et al. Long-term outcomes-mycophenolate mofetil treatment for lupus nephritis with addition of tacrolimus for resistant cases. Nephrol Dial Transplant 2010; 25: 3939-3948.
21. Ramos-Casals M, Soto MJ, Cuadrado MJ et al. Rituximab in systemic lupus erythematosus A systematic review of off-label use in 188 cases. Lupus 2009; 18: 767-776.
22. Cattran D. Management of membranous nephropathy: when and what for treatment. J Am Soc Nephrol 2005; 16: 1188-1194.
23. Cattran DC, Pei Y, Greenwood CMT et al. Validation of a predictive model of idiopathic membranous nephropathy: Its clinical and research implications. Kidney Int 1997; 51: 901-907.
24. Polanco N, Gutierrez E, Covarsi A et al. Spontaneous remission of nephrotic syndrome in idiopathic membranous nephropathy. J Am Soc Nephrol 2010; 21: 697-704.
25. Hladunewich MA, Troyanov S, Calafati J et al. The natural history of the non-nephrotic membranous nephropathy patient. Clin J Am Soc Nephrol 2009; 4: 1417-1422.
26. Lionaki S. Venous thromboembolism in patients with membranous nephropathy. J Am Soc Nephrol 2012; 7: 43-51.
27. Hofstra JM, Branten AJW, Wirtz JJJM et al. Early versus late start of immunosuppressive therapy in idiopathic membranous nephropathy: a randomized controlled trial. Nephrol Dial Transplant 2010; 25: 129-136.
28. Ponticelli C, Zucchelli P. A 10-year follow-up of a randomized study with methylprednisolone and chlorambucil in membranous nephropathy. Kidney Int 1995; 48: 1600-1604.
29. Ponticelli C, Zucchelli P, Passerini P et al. A Randomized trial of methylprednisolone and chlorambucil in idiopathic membranous nephropathy. N Eng J Med 1989; 320: 8-13.
30. Cattran DC, Appel GB, Hebert LA et al. Cyclosporine in patients with steroid-resistant membranous nephropathy: A randomized trial. Kidney Int 2001; 59: 1484-1490.
31. Praga M, Barrio V, Juarez GF et al. Tacrolimus monotherapy in membranous nephropathy: A randomized controlled trial. Kidney Int 2007; 71: 924-930.
32. Donadio JV, Bergstralh EJ, Grande JP et al. Proteinuria patterns and their association with subsequent end-stage renal disease in IgA nephropathy. Nephrol Dial Transplant 2002; 17: 1197-1203.
33. Reich HN, Troyanov S, Scholey JW et al. Remission of proteinuria improves prognosis in IgA nephropathy. J Am Soc Nephrol 2007; 18: 3177-3183.
34. Kanno Y, Okada H, Saruta T et al. Blood pressure reduction associated with preservation of renal function in hypertensive patients with IgA nephropathy: a 3-year follow-up. Clin Nephrol 2000; 54: 360-365.
35. Roberts ISD, Cook HT, Troyanov S et al. The Oxford classification of IgA nephropathy: pathology definitions, correlations, and reproducibility. Kidney Int 2009; 76: 546-556.
36. Praga M, Gutierrez E, Gonzalez E et al. Treatment of IgA nephropathy with ACE inhibitors: a randomized and controlled trial. J Am Soc Nephrol 2003; 14: 1578-1583.
37. Manno C, Torres DD, Rossini M et al. Randomized controlled clinical trial of corticosteroids plus ACE-inhibitors with long-term follow-up in proteinuric IgA nephropathy. Nephrol Dial Transplant 2009; 24: 3694-3701.
38. Lv JC, Zhang H, Chen YQ et al. Combination therapy of prednisone and ACE inhibitor versus ACE-inhibitor therapy alone in patients with IgA nephropathy: a randomized controlled trial. Am J Kid Dis 2009; 53: 26-32.
39. Stone JH, Merkel PA, Spiera R et al. Rituximab versus cyclophosphamide for ANCA-associated vasculitis. N Eng J Med 2010; 363: 221-232.
40. Lauque D, Cadranel J, Lazor R et al. Microscopic polyangiitis with alveolar hemorrhage-a study of 29 cases and review of the literature. Medicine 2000; 79: 222-233.
41. Klemmer PJ, Chalermskulrat W, Reif MS et al. Plasmapheresis therapy for diffuse alveolar hemorrhage in patients with small-vessel vasculitis. Am J Kid Dis 2003; 42: 1149-1153.
42. Nachman PH, Hogan SL, Jennette JC et al. Treatment response and relapse in antineutrophil cytoplasmic autoantibody-associated microscopic polyangiitis and glomerulonephritis. J Am Soc Nephrol 1996; 7: 33-39.
43. Holguin F, Ramadan B, Gal AA et al. Prognostic factors for hospital mortality and ICU admission in patients with ANCA-Related pulmonary vasculitis. Am J Med Sci 2008; 336: 321-326.